Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| ALKERMES (NASDAQ: ALKS) | Delayed: 43.84 -0.27 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.11 | 52 Week High | $80.71 | |||
| Open | $44.12 | 52 Week Low | $27.14 | |||
| Day High | $44.58 | P/E | 337.23 | |||
| Day Low | $43.59 | EPS | $0.13 | |||
| Volume | 1,071,952 | |||||
